Award
NIH Reporter #5R01AI184416-02
Therapeutic drug monitoring for linezolid in the treatment of rifampin-resistant tuberculosis: a pragmatic randomized controlled trial
Recipient
National Institute of Allergy and Infectious Diseases
Award Amount
$464,199.00
Ceiling
$464,199.00
Awarded
December 09, 2025
Identifier
5R01AI184416-02
NIH grant awarded to support research on therapeutic drug monitoring of linezolid in rifampin-resistant tuberculosis patients in South Africa, involving a pragmatic randomized controlled trial.
Description
This NIH grant supports research on the efficacy of therapeutic drug monitoring of linezolid to prevent toxicity in RR-TB patients, with a focus on South Africa. The project involves randomized controlled trial design, population PK modeling, and assessment of adverse effects.